Mayur Narkhede is an Oncology physician affiliated with University of Alabama at Birmingham. OpenAlex indexes 97 publications with 1,030 citations (h-index 14); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2000 6th Ave S
Birmingham, AL 352332110
Telephone
205-934-9999Provider last certified this registry record 20 Apr 2026.
Clinical trials
- PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL
Sponsor: University of Alabama at Birmingham
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
22 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- BeOne Medicines USA, Inc.Program year202520 payments$30,593openpaymentsdata.cms.gov ↗
- Lilly USA, LLCProgram year20257 payments$14,400openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year202517 payments$11,772openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
39.5%Kinase inhibitor31%Calquence43%Brukinsa28%Imbruvica16%Jaypirca12%Part D<11 patientsBCL-2 Inhibitor8.5%Venclexta100%Part D<11 patientsMetabolism & gastrointestinal
17%Corticosteroid10.7%Prednisone100%Part D≥21 patientsSerotonin-3 Receptor Antagonist6.3%Ondansetron Hcl100%Part D≥20 patientsDermatology
14.6%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor14.6%Acyclovir100%Part D≥20 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Immune Dysfunction and Consequences in Chronic Lymphocytic Leukemia
Journal of the National Comprehensive Cancer Network
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Vera Bittner
University of Alabama at Birmingham
Richard Whitley, MD
University of Alabama at Birmingham
David Standaert, MD, PhD
University of Alabama at Birmingham
Erik Roberson
University of Alabama at Birmingham
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”